Shrinking or Delayed Expenditure of Capital Budgets

The life science industry has not been immune to the effects of the economic downturn and the "do more with less" mantra driving all industries over the last few years. Once typical $300+ million greenfield projects have given way to smaller expansions and retrofits of exisiting facilities. FW Biokinetics is uniquely positioned to assist our customers with these current trends in the marketplace. We are well known in the industry for our ability to execute small to mid-sized projects.

Now, as part of Foster Wheeler, we come with the backing of a four billion dollar global organization employing more than 12,000 highly skilled professionals in over 28 countries. Foster Wheeler's reputation for safely delivering quality projects on time and on budget is well recognized. We have proven expertise in managing large, complex projects, a global reach and longstanding international presence, strong client relationships and cutting-edge processes and technologies. It just makes sense to go to the bioprocess engineers you have always relied on who can now provide you with the added strength and reliability of Foster Wheeler to get you across the finish line.

As companies are delaying capital investments, they are looking to get more production out of their existing facilities. Getting more production out of an existing facility is a complex puzzle requiring changes to process equipment, piping, automation, utilities, production schedules, staffing, warehousing, and so on. Our simulation, process and facilities expertise positions us well to provide solutions to optimizing these facilities. FW Biokinetics has performed optimization exercises for many facilities, identifying how to increase capacity while minimizing the effect on existing production. The value of simulation is that it visualizes both the plant limitations and the effectiveness of the solution. In addition, it enables us to evaluate multiple scenarios. This combination of challenging scenarios and visual confirmation leads to a high degree of confidence in the solution and a rapid move towards execution.

You need an objective way to effectively present alternatives. Hundreds of pharmaceutical company projects have chosen K-TOPS® process optimization to accomplish this. Developed exclusively for the biotechnology and pharmaceutical industry, the power of K-TOPS® is in its ability to clearly evaluate alternatives - this is not a plug it in, spit it out program, but instead a business tool used by CFOs and engineering managers alike, to give managers a clear view of process alternatives.

To learn more, check out our K-TOPS® brochure or click here to contact us.